Journey Medical Corp v. Lupin Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Journey Medical Corporation (Delaware)
  • Defendant: Lupin Limited (India); Lupin Pharmaceuticals, Inc. (Delaware)
  • Plaintiff's Counsel: Shaw Keller LLP; Norton Rose Fulbright US LLP
• Case Identification: 1:26-cv-00202, D. Del., 04/17/2026
• Venue Allegations: Plaintiff alleges venue is proper in Delaware because Defendant Lupin Pharmaceuticals is incorporated there, both Defendants conduct continuous business in the state, and Defendants have previously availed themselves of the court's jurisdiction in prior Hatch-Waxman litigation.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's EMROSIT™ product constitutes an act of infringement of four U.S. patents directed to methods of treating inflammatory skin conditions with low-dose minocycline.
• Technical Context: The technology involves the use of specific low-dose formulations of minocycline, an antibiotic, to provide an anti-inflammatory effect for treating chronic skin conditions like rosacea while minimizing dose-related side effects.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following a notice letter dated January 20, 2026, in which Lupin Limited informed Journey of its ANDA filing (No. 221130) with a Paragraph IV certification. Lupin asserts that U.S. Patent Nos. 10,905,664, 11,191,740, and 11,364,212 will not be infringed and/or are invalid. Three of the asserted patents are listed in the FDA's Orange Book for EMROSIT™; the most recent patent was submitted for listing just one day prior to the filing of this complaint.

Case Timeline

Date	Event
2018-01-07	Earliest Priority Date for all Asserted Patents
2021-02-02	U.S. Patent No. 10,905,664 Issued
2021-12-07	U.S. Patent No. 11,191,740 Issued
2022-06-21	U.S. Patent No. 11,364,212 Issued
2026-01-20	Lupin Limited sends Paragraph IV Notice Letter
2026-01-21	Journey receives Notice Letter
2026-04-07	U.S. Patent No. 12,594,252 Issued
2026-04-16	Journey submits the '252 patent for Orange Book listing
2026-04-17	Amended Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,905,664 - "Methods for treating inflammatory skin conditions" (issued 02/02/2021)

The Invention Explained

• Problem Addressed: The patent addresses the need for a treatment for inflammatory skin conditions like rosacea that is both effective and has a favorable side-effect profile. It notes that existing treatments, such as higher doses of minocycline, are associated with adverse events like vestibular issues (e.g., vertigo), and other antibiotics like doxycycline can cause esophageal irritation, limiting patient compliance and long-term use ʼ664 Patent, col. 3:1-17
• The Patented Solution: The invention is a method for treating rosacea by administering a "reduced dose" of minocycline, specifically a body-weight independent dose of about 10 mg to 40 mg. This method is designed to achieve a specific pharmacokinetic (PK) profile, including a steady-state maximum plasma concentration (Cmaxssp) of not more than 500 ng/ml, which provides an anti-inflammatory effect sufficient to reduce lesions while minimizing the side effects associated with higher, antimicrobial doses '664 Patent, abstract '664 Patent, col. 4:13-16 '664 Patent, claim 1
• Technical Importance: The invention provides a method to repurpose an existing antibiotic at a sub-antimicrobial dose, aiming to create a safer long-term therapy for a chronic condition by separating the drug's anti-inflammatory properties from its antimicrobial effects and associated side effects '664 Patent, col. 3:20-33

Key Claims at a Glance

• The complaint asserts infringement of independent claim 1 Compl. ¶44
• Essential elements of independent claim 1 include:
  • A method of treating rosacea in a subject in need thereof, comprising administering an oral pharmaceutical composition comprising a body-weight independent dose of about 10 mg to about 40 mg of minocycline;
  • Wherein Cmax in the subject's plasma is achieved at about 1.75 hours after administration and Cmaxssp of minocycline is not more than about 500 ng/ml;
  • Wherein the rosacea is one of several specified types (e.g., papulopustular rosacea);
  • Wherein the administration reduces the Investigator's Global Assessment (IGA) score by at least one grade; and
  • Wherein the administration reduces the number of inflammatory lesions by at least about 60%.
• The complaint reserves the right to assert additional claims Compl. ¶44

U.S. Patent No. 11,191,740 - "Methods for treating inflammatory skin conditions" (issued 12/07/2021)

The Invention Explained

• Problem Addressed: As with the related '664 patent, this patent seeks to provide a safe and effective low-dose minocycline treatment for inflammatory skin conditions like rosacea, avoiding the side effects associated with higher antibiotic doses '740 Patent, col. 3:1-24
• The Patented Solution: The patent claims a method of treating rosacea using a 10 mg to 40 mg dose of minocycline. This method is defined by achieving a specific maximum plasma concentration (Cmaxp) of about 55 ng/ml to 450 ng/ml and providing "equivalent or improved efficacy" compared to a 40 mg oral doxycycline composition '740 Patent, abstract '740 Patent, claim 1 The solution is thus a specific dosing regimen intended to optimize the therapeutic window for minocycline's anti-inflammatory effects.
• Technical Importance: This approach provided a new therapeutic option for rosacea that was benchmarked against the standard low-dose doxycycline treatment, claiming to offer comparable or superior efficacy with a distinct active ingredient and PK profile '740 Patent, col. 4:35-40

Key Claims at a Glance

• The complaint asserts infringement of independent claim 1 Compl. ¶64
• Essential elements of independent claim 1 include:
  • A method of treating rosacea in a subject in need thereof, comprising administering an oral pharmaceutical composition with a body-weight independent dose of about 10 mg to 40 mg of minocycline;
  • Wherein the composition results in a Cmaxp of about 55 ng/ml to about 450 ng/ml;
  • Wherein the composition provides equivalent or improved efficacy as compared to a 40 mg oral doxycycline composition;
  • Wherein the administration reduces the IGA score by at least one grade; and
  • Wherein the administration reduces the number of inflammatory lesions by at least about 60%.
• The complaint reserves the right to assert additional claims Compl. ¶64

U.S. Patent No. 11,364,212 - "Methods for treating inflammatory skin conditions" (issued 06/21/2022)

• Technology Synopsis: As a continuation of the prior patents, this patent discloses methods for treating rosacea with a 10-40 mg body-weight independent dose of minocycline. The claims are defined by the resulting clinical and pharmacokinetic outcomes, including achieving a steady-state maximum interstitial fluid concentration (CmaxSSIF) of not more than 200 ng/ml, which is intended to provide anti-inflammatory effects while minimizing side effects associated with higher systemic exposure '212 Patent, abstract '212 Patent, claim 1
• Asserted Claims: Independent claim 1 is asserted Compl. ¶84
• Accused Features: The use of Lupin's 40 mg minocycline ANDA product as directed by its proposed label for treating rosacea is alleged to infringe, with the complaint stating this use will meet the dosage and method limitations of the patent Compl. ¶¶91-92

U.S. Patent No. 12,594,252 - "Methods for treating inflammatory skin conditions" (issued 04/07/2026)

• Technology Synopsis: This patent, also in the same family, claims methods for treating inflammatory lesions and/or erythema of rosacea by administering a 10-40 mg dose of minocycline. The claims are characterized by specific clinical outcomes, such as a one-grade reduction in IGA score and at least a 60% reduction in inflammatory lesions, tied to particular pharmacokinetic parameters including a Cmaxp of about 55 ng/ml to 450 ng/ml '252 Patent, abstract '252 Patent, claim 1
• Asserted Claims: Independent claim 1 is asserted Compl. ¶104
• Accused Features: The use of Lupin's 40 mg minocycline ANDA product as directed by its proposed label for treating rosacea is alleged to infringe, with the complaint stating this use will meet the dosage and method limitations of the patent Compl. ¶¶109-110

III. The Accused Instrumentality

Product Identification

Lupin's Abbreviated New Drug Application (ANDA) Product, identified as a generic minocycline hydrochloride, extended-release 40 mg capsule for which Lupin filed ANDA No. 221130 Compl. ¶2

Functionality and Market Context

The accused product is a generic equivalent to Journey's branded drug, EMROSIT™. The complaint alleges that Lupin's proposed label for its ANDA product is "substantially identical" to the EMROSIT™ label and instructs its use for the "treat[ment of] inflammatory lesions (papules and pustules) of rosacea in adults" Compl. ¶¶48-49 Compl. ¶¶68-69 The infringement allegation is not based on the composition of the product itself, but on the method of use that its label will induce physicians to prescribe and patients to perform Compl. ¶52 Compl. ¶72 The product's commercial importance stems from its position as a generic alternative intended to displace sales of the branded EMROSIT™ upon FDA approval Compl. ¶26

IV. Analysis of Infringement Allegations

'664 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating rosacea in a subject in need thereof, comprising administering an oral pharmaceutical composition comprising a body-weight independent dose of about 10 mg to about 40 mg of minocycline...	The proposed label for Lupin's ANDA product allegedly instructs and encourages administering a 40 mg dose for the treatment of rosacea.	¶52	col. 4:13-16
...wherein Cmax in the subject's plasma is achieved at about 1.75 hours after administration and Cmaxssp of minocycline is not more than about 500 ng/ml...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation, including the specified pharmacokinetic parameters.	¶51	col. 5:38-41
...wherein said rosacea is selected from papulopustular rosacea, erythematotelangiectatic rosacea, phymatous rosacea, ocular rosacea, pyoderma faciale, rosacea conglobate and combinations thereof...	The proposed label allegedly instructs use for treating inflammatory lesions of rosacea, which encompasses the claimed types.	¶49	col. 11:6-14
...wherein the administration of the oral pharmaceutical composition reduces the IGA score of the subject by at least one grade...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation, including the specified efficacy outcomes.	¶51	col. 5:6-10
...and reduces the number of inflammatory lesions of the subject by at least about 60% as compared to the number of inflammatory lesions before administration...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation, including the specified efficacy outcomes.	¶51	col. 5:23-28

'740 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating rosacea in a subject in need thereof, comprising administering an oral pharmaceutical composition comprising a body-weight independent dose of about 10 mg to about 40 mg of minocycline...	The proposed label for Lupin's ANDA product allegedly instructs administering a 40 mg dose for the treatment of rosacea.	¶72	col. 4:14-16
...wherein the said composition results in a maximum plasma concentration (Cmaxp) of about 55 ng/ml to about 450 ng/ml of minocycline...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation, including the specified pharmacokinetic parameters.	¶71	col. 33:43-45
...wherein said composition provides equivalent or improved efficacy as compared to the oral doxycycline composition comprising 40 mg of doxycycline...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation.	¶71	col. 4:37-40
...wherein said composition reduces the IGA score of the subject by at least one grade...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation, including the specified efficacy outcomes.	¶71	col. 5:6-10
...and wherein said composition reduces the number of inflammatory lesions of the subject by at least about 60%...	The complaint alleges that the use of Lupin's ANDA product as directed by its labeling will meet each claim limitation, including the specified efficacy outcomes.	¶71	col. 5:23-28

Identified Points of Contention

• Scope Questions: The infringement analysis for these method-of-use claims will raise questions about whether the instructions on Lupin's proposed label will inevitably lead to a direct infringement by users. A key dispute may be whether the pharmacokinetic and efficacy parameters recited in the claims (e.g., Cmaxssp not more than 500 ng/ml, 60% lesion reduction) are guaranteed outcomes of the prescribed use or merely potential results, which could impact the inducement analysis.
• Technical Questions: A primary technical question is whether Lupin's 40 mg formulation is bioequivalent to a formulation that actually produces the specific PK profiles claimed in the patents. The complaint alleges that the use of Lupin's product will meet the limitations, but this suggests the possibility of a factual dispute over the actual PK and clinical performance of the accused generic product when used as directed.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

Term: "reduces the number of inflammatory lesions of the subject by at least about 60%" (from claim 1 of the '664 and '740 patents)

• Context and Importance: This efficacy-based limitation is a critical battleground. Its interpretation will determine the evidentiary burden on the patentee. Practitioners may focus on this term because if it is construed to require this specific outcome in every single patient, proving induced infringement becomes more difficult, as a defendant could argue that the label does not induce infringement for any patient who fails to achieve this result.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent specifications present this reduction as an expected outcome of the method, supported by clinical trial data showing this average effect '664 Patent, Table 10 '740 Patent, Table 10 A plaintiff may argue that the claim should be read to cover a method that is designed and proven to achieve this result in a clinically significant patient population, consistent with how drugs are approved and prescribed.
  • Evidence for a Narrower Interpretation: The plain language "reduces" is an active verb, suggesting the reduction must actually occur for the method to be practiced. A defendant may point to clinical trial data, including figures in the patents, that show a distribution of patient responses, arguing that since not all subjects achieve a 60% reduction, the label does not induce infringement in all cases '664 Patent, Fig. 5 '740 Patent, Fig. 5

Term: "body-weight independent dose" (from claim 1 of the '664 and '740 patents)

• Context and Importance: This term defines the nature of the claimed dosing regimen. Its construction is important for distinguishing the invention from prior art or alternative treatments that may involve weight-based dose adjustments.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification consistently refers to a fixed dose range of "about 10 mg to about 40 mg" without any mention of adjusting for patient weight, which supports a reading that the dose is predetermined and not titrated '664 Patent, col. 4:51-56 '740 Patent, col. 4:51-56
  • Evidence for a Narrower Interpretation: A defendant might argue that the term requires that the dose have no correlation with body weight whatsoever. They could probe whether standard medical practice might lead a physician to select a dose within the claimed range (e.g., 20 mg vs. 40 mg) based in part on a patient's size, potentially raising a question about whether such a practice falls outside the claim scope.

VI. Other Allegations

• Indirect Infringement: The complaint's infringement theory rests entirely on indirect infringement. It alleges induced infringement on the basis that Lupin's proposed product labeling will actively instruct and encourage healthcare professionals and patients to administer the generic product according to the patented methods (Compl. ¶¶52; 56; 72; 76). It also pleads contributory infringement, alleging that Lupin's product is not a staple article of commerce and lacks substantial non-infringing uses Compl. ¶58 Compl. ¶78
• Willful Infringement: Willfulness is alleged based on both pre- and post-suit knowledge. The complaint asserts that Lupin had actual knowledge of the '664, '740, and '212 patents because they are listed in the FDA's Orange Book for EMROSIT™ (Compl. ¶¶59; 79; 99). For the '252 patent, knowledge is alleged based on Lupin's "monitoring of patent applications" Compl. ¶117 The complaint argues that Defendants' decision to proceed with the ANDA filing despite this knowledge lacks a reasonable basis and renders the infringement willful and the case "exceptional" under 35 U.S.C. § 285 (Compl. ¶¶60; 80; 100; 118).

VII. Analyst's Conclusion: Key Questions for the Case

1. Evidentiary Burden for Method Claims: A central issue will be one of proof: can Journey demonstrate that the administration of Lupin's 40 mg capsule, as directed by its proposed label, will necessarily and consistently result in the specific pharmacokinetic and clinical efficacy outcomes recited in the claims (e.g., Cmaxssp below 500 ng/ml, a 60% lesion reduction)? Proving that a label induces a method defined by specific patient outcomes is a known challenge in ANDA litigation.
2. Claim Construction of Efficacy Limitations: The case will likely turn on a question of definitional scope: how will the court construe the efficacy requirement "reduces the number of inflammatory lesions... by at least about 60%"? The resolution of whether this requires the outcome in all, most, or a clinically significant portion of patients will be critical to the infringement analysis.
3. Validity of Pharmacokinetic and Efficacy-Defined Claims: While not detailed in the complaint, Lupin's Paragraph IV certification challenges the validity of the patents. A key question for the court will be whether the combination of a known dosage range with specific pharmacokinetic parameters and clinical efficacy results, which can vary among patients, renders the claims invalid as obvious or lacking enablement/written description.